Angitia Biopharmaceuticals

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals, founded in 2018, is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Their mission is to address unmet medical needs and bring breakthrough therapies to patients.

Products & Services

AGA2115:A bispecific antibody for the treatment of Osteogenesis Imperfecta, with recent first-in-human data and Orphan Drug Designation from the European Medicines Agency.

Pipeline for Musculoskeletal Diseases:Focuses on therapies for conditions including Degenerative Disc Disease, Osteoporosis, Osteogenesis Imperfecta, Bone Metastasis, Nonunion, Osteoarthritis, and Muscle Disorders.

Specialties

Musculoskeletal Diseases Drug Development for Degenerative Disc Disease Osteoporosis Osteogenesis Imperfecta Bone Metastasis Nonunion Osteoarthritis Muscle Disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 130000000 MR: - FA: 130 million FAN: 130000000	D: 2026-02-05 FD: 2026-02-05	18 investors
2	RT: Series C T: - FT: Series C	A: 120000000 MR: - FA: $120 million FAN: 120000000	D: 2024-12-11 FD: 2024-12-11	7 investors

Series D Latest

2026-02-05

$130.0M

18 investors (Pro only)

Series C 2024-12-11

$120.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Hua Zhu (David) Ke

Founder, Chairman, CEO

W

Willard Dere

Chief Medical Officer, Chief Advisor to CEO

M

Muyu (Luna) Li

Co-founder, Chief Operating Officer

M

Michael H. Arenberg

Chief Financial Officer

L

Lei Zheng

Chief Technology Officer

X

Xiaofeng Liu

Head of Discovery Research

View 8 more team members with Pro

Unlock Full Team Directory

Recent News